JP2014526447A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014526447A5 JP2014526447A5 JP2014528879A JP2014528879A JP2014526447A5 JP 2014526447 A5 JP2014526447 A5 JP 2014526447A5 JP 2014528879 A JP2014528879 A JP 2014528879A JP 2014528879 A JP2014528879 A JP 2014528879A JP 2014526447 A5 JP2014526447 A5 JP 2014526447A5
- Authority
- JP
- Japan
- Prior art keywords
- nasal
- nose
- carrier material
- powder
- inhaled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102011112978A DE102011112978A1 (de) | 2011-09-09 | 2011-09-09 | Benzonitrilderivate |
| DE102011112978.6 | 2011-09-09 | ||
| PCT/EP2012/003449 WO2013034238A1 (de) | 2011-09-09 | 2012-08-13 | Benzonitrilderivate als kinasehemmer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014526447A JP2014526447A (ja) | 2014-10-06 |
| JP2014526447A5 true JP2014526447A5 (enExample) | 2015-10-01 |
| JP6060163B2 JP6060163B2 (ja) | 2017-01-11 |
Family
ID=46679243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014528879A Expired - Fee Related JP6060163B2 (ja) | 2011-09-09 | 2012-08-13 | キナーゼインヒビターとしてのベンゾニトリル誘導体 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8969335B2 (enExample) |
| EP (1) | EP2753615B1 (enExample) |
| JP (1) | JP6060163B2 (enExample) |
| KR (1) | KR101985984B1 (enExample) |
| CN (1) | CN103930416B (enExample) |
| AR (1) | AR087807A1 (enExample) |
| AU (1) | AU2012306746B2 (enExample) |
| BR (1) | BR112014005226A2 (enExample) |
| CA (1) | CA2848148C (enExample) |
| DE (1) | DE102011112978A1 (enExample) |
| DK (1) | DK2753615T3 (enExample) |
| EA (1) | EA025038B1 (enExample) |
| ES (1) | ES2644128T3 (enExample) |
| HR (1) | HRP20171296T1 (enExample) |
| HU (1) | HUE036774T2 (enExample) |
| IL (1) | IL231382A (enExample) |
| IN (1) | IN2014KN00769A (enExample) |
| LT (1) | LT2753615T (enExample) |
| MX (1) | MX344335B (enExample) |
| NO (1) | NO2753615T3 (enExample) |
| PL (1) | PL2753615T3 (enExample) |
| PT (1) | PT2753615T (enExample) |
| RS (1) | RS56481B1 (enExample) |
| SG (1) | SG2014015234A (enExample) |
| SI (1) | SI2753615T1 (enExample) |
| WO (1) | WO2013034238A1 (enExample) |
| ZA (1) | ZA201402561B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104271566B (zh) * | 2012-05-22 | 2017-05-31 | 霍夫曼-拉罗奇有限公司 | 取代的联吡啶胺及其用途 |
| GB201303109D0 (en) | 2013-02-21 | 2013-04-10 | Domainex Ltd | Novel pyrimidine compounds |
| JP6523251B2 (ja) | 2013-05-01 | 2019-05-29 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｃ−結合ヘテロシクロアルキル置換ピリミジン類及びそれらの用途 |
| SG11201608303QA (en) | 2014-04-04 | 2016-11-29 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| TW201613916A (en) | 2014-06-03 | 2016-04-16 | Gilead Sciences Inc | TANK-binding kinase inhibitor compounds |
| CN104201295B (zh) * | 2014-09-16 | 2017-05-03 | 深圳市华星光电技术有限公司 | Oled的封装方法及oled结构 |
| NZ729618A (en) | 2014-09-26 | 2018-07-27 | Gilead Sciences Inc | Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds |
| WO2016057338A1 (en) * | 2014-10-06 | 2016-04-14 | Takeda Pharmaceutical Company Limited | Heteroarylamide inhibitors of tbk1 |
| CN106854174A (zh) * | 2015-12-08 | 2017-06-16 | 湖南华腾制药有限公司 | 一种4位取代哌啶衍生物的制备方法 |
| CU20180059A7 (es) * | 2015-12-17 | 2018-10-04 | Gilead Sciences Inc | Compuestos inhibidores de la quinasa de unión a tank |
| EP3390387B1 (en) | 2015-12-18 | 2021-11-17 | Bayer Pharma Aktiengesellschaft | Heteroarylbenzimidazole compounds |
| CN107286076A (zh) * | 2016-04-05 | 2017-10-24 | 湖南华腾制药有限公司 | 一种哌啶类化合物的制备方法 |
| CN107400082A (zh) * | 2016-05-19 | 2017-11-28 | 湖南华腾制药有限公司 | 一种取代哌啶衍生物的制备方法 |
| WO2017207534A1 (en) | 2016-06-03 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituted heteroarylbenzimidazole compounds |
| DE102016113714A1 (de) | 2016-07-26 | 2018-02-01 | Rosa Karl | Transfektionsverfahren mit nicht-viralen Genliefersystemen |
| CN107698491A (zh) * | 2016-08-08 | 2018-02-16 | 湖南华腾制药有限公司 | 一种取代哌啶衍生物的制备方法 |
| CN107778216A (zh) * | 2016-08-30 | 2018-03-09 | 湖南华腾制药有限公司 | 一种氟取代哌啶衍生物的制备方法 |
| CN107778215A (zh) * | 2016-08-30 | 2018-03-09 | 湖南华腾制药有限公司 | 一种氟取代哌啶衍生物的制备方法 |
| CN108117510A (zh) * | 2016-11-29 | 2018-06-05 | 湖南华腾制药有限公司 | 一种哌啶衍生物的制备方法 |
| CN108610309A (zh) * | 2016-12-13 | 2018-10-02 | 湖南华腾制药有限公司 | 一种哌啶衍生物的制备方法 |
| GB201702947D0 (en) | 2017-02-23 | 2017-04-12 | Domainex Ltd | Novel compounds |
| SG11202003407VA (en) * | 2017-10-17 | 2020-05-28 | Merck Patent Gmbh | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF |
| AU2018352701A1 (en) * | 2017-10-17 | 2020-06-04 | Merck Patent Gmbh | Pyrimidine ΤΒΚ/ΙΚΚE inhibitor compounds and uses thereof |
| WO2020118683A1 (en) * | 2018-12-14 | 2020-06-18 | Lynk Pharmaceuticals Co. Ltd. | Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof |
| WO2020206588A1 (en) * | 2019-04-08 | 2020-10-15 | Lynk Pharmaceuticals Co., Ltd. | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof |
| CN110627775B (zh) * | 2019-10-24 | 2026-01-30 | 特科罗生物科技(成都)有限公司 | 一种小分子化合物 |
| CN112209886A (zh) * | 2020-11-09 | 2021-01-12 | 沈阳药科大学 | 2-(3-氰基-4-烷氧基)苯基嘧啶衍生物及其制备方法和用途 |
| CN113024565B (zh) * | 2021-03-31 | 2022-09-13 | 上海启甄环境科技有限公司 | 一种放射性同位素碳-14标记依鲁替尼及其合成方法 |
| WO2024239282A1 (zh) * | 2023-05-24 | 2024-11-28 | 凌科药业(杭州)有限公司 | 一种药物组合物、外用制剂及其制备方法、应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| GB9904387D0 (en) | 1999-02-25 | 1999-04-21 | Pharmacia & Upjohn Spa | Antitumour synergistic composition |
| AU2003262642B2 (en) * | 2002-08-14 | 2010-06-17 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| SE0203754D0 (sv) | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| EP1648875A1 (en) | 2003-07-30 | 2006-04-26 | Cyclacel Limited | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
| JP2009535386A (ja) | 2006-05-03 | 2009-10-01 | アストラゼネカ アクチボラグ | チアゾール誘導体および抗腫瘍剤としてのその使用 |
| US20080153822A1 (en) | 2006-11-30 | 2008-06-26 | Martin Augustin | Methods of treating pain |
| KR101566840B1 (ko) | 2007-03-12 | 2015-11-06 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
| WO2009030890A1 (en) | 2007-09-03 | 2009-03-12 | University Court Of The University Of Dundee | Pyrimidine compounds for the treatment of cancer, septic shock and/or primary open angle glaucoma |
| JP5611826B2 (ja) | 2007-09-04 | 2014-10-22 | ザ スクリプス リサーチ インスティテュート | タンパク質キナーゼ阻害剤としての置換されたピリミジニル−アミン |
| JP2011500778A (ja) | 2007-10-25 | 2011-01-06 | アストラゼネカ・アクチエボラーグ | ピリジン及びピラジン誘導体−０８３ |
| US20100056524A1 (en) | 2008-04-02 | 2010-03-04 | Mciver Edward Giles | Compound |
| GB0903759D0 (en) | 2009-03-04 | 2009-04-15 | Medical Res Council | Compound |
| WO2010151747A1 (en) * | 2009-06-26 | 2010-12-29 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimine compounds and methods of making and using same |
| EP2488503A1 (en) | 2009-10-12 | 2012-08-22 | Myrexis, Inc. | Amino - pyrimidine compounds as inhibitors of tbkl and/or ikk epsilon |
| GB201012105D0 (en) | 2010-07-19 | 2010-09-01 | Domainex Ltd | Novel pyrimidine compounds |
| JP2014500254A (ja) * | 2010-11-09 | 2014-01-09 | セルゾーム リミティッド | Ｔｙｋ２阻害剤としてのピリジン化合物およびそのアザ類似体 |
| MX2013011908A (es) * | 2011-04-12 | 2014-03-27 | Alzheimer S Inst Of America Inc | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. |
-
2011
- 2011-09-09 DE DE102011112978A patent/DE102011112978A1/de not_active Withdrawn
-
2012
- 2012-08-13 LT LTEP12747896.4T patent/LT2753615T/lt unknown
- 2012-08-13 EA EA201400333A patent/EA025038B1/ru not_active IP Right Cessation
- 2012-08-13 HR HRP20171296TT patent/HRP20171296T1/hr unknown
- 2012-08-13 HU HUE12747896A patent/HUE036774T2/hu unknown
- 2012-08-13 CA CA2848148A patent/CA2848148C/en active Active
- 2012-08-13 ES ES12747896.4T patent/ES2644128T3/es active Active
- 2012-08-13 BR BR112014005226A patent/BR112014005226A2/pt not_active IP Right Cessation
- 2012-08-13 EP EP12747896.4A patent/EP2753615B1/de active Active
- 2012-08-13 CN CN201280043591.XA patent/CN103930416B/zh not_active Expired - Fee Related
- 2012-08-13 WO PCT/EP2012/003449 patent/WO2013034238A1/de not_active Ceased
- 2012-08-13 JP JP2014528879A patent/JP6060163B2/ja not_active Expired - Fee Related
- 2012-08-13 MX MX2014002683A patent/MX344335B/es active IP Right Grant
- 2012-08-13 SG SG2014015234A patent/SG2014015234A/en unknown
- 2012-08-13 NO NO12747896A patent/NO2753615T3/no unknown
- 2012-08-13 SI SI201231093T patent/SI2753615T1/sl unknown
- 2012-08-13 DK DK12747896.4T patent/DK2753615T3/en active
- 2012-08-13 AU AU2012306746A patent/AU2012306746B2/en not_active Ceased
- 2012-08-13 PL PL12747896T patent/PL2753615T3/pl unknown
- 2012-08-13 US US14/342,911 patent/US8969335B2/en not_active Expired - Fee Related
- 2012-08-13 IN IN769KON2014 patent/IN2014KN00769A/en unknown
- 2012-08-13 PT PT127478964T patent/PT2753615T/pt unknown
- 2012-08-13 RS RS20171056A patent/RS56481B1/sr unknown
- 2012-08-13 KR KR1020147008982A patent/KR101985984B1/ko not_active Expired - Fee Related
- 2012-09-07 AR ARP120103304A patent/AR087807A1/es not_active Application Discontinuation
-
2014
- 2014-03-06 IL IL231382A patent/IL231382A/en active IP Right Grant
- 2014-04-08 ZA ZA2014/02561A patent/ZA201402561B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014526447A5 (enExample) | ||
| JP2013544781A5 (enExample) | ||
| JP2014509313A5 (enExample) | ||
| JP2013534227A5 (enExample) | ||
| JP2015505541A5 (enExample) | ||
| JP2013541565A5 (enExample) | ||
| Weber et al. | Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art | |
| Doktorovova et al. | Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo evaluation | |
| Yang et al. | Pulmonary drug delivery by powder aerosols | |
| EA201590286A1 (ru) | Аэрозольное ингаляционное устройство | |
| WO2014074797A8 (en) | Ultra low density pulmonary powders | |
| TN2015000395A1 (en) | Respirable agglomerates of porous carrier particles and micronized drug | |
| UA112296C2 (uk) | Сухий порошковий препарат, який містить інгібітор фосфодіестерази | |
| IN2014DN09377A (enExample) | ||
| UA107499C2 (uk) | Склад сухого порошку, який містить антимускариновий засіб | |
| UA117685C2 (uk) | Складена композиція для перорального введення, яка містить езетиміб та розувастатин | |
| PH12012500631A1 (en) | Improvements to pressurised metered dose inhalers | |
| MY191380A (en) | Stabilized fixed dose drug composition having mometasone and olopatadine | |
| MX2016007181A (es) | Medicamentos inhalables. | |
| MX373138B (es) | Inhalador de polvo seco y método de uso. | |
| EA201700182A1 (ru) | Состав для повышения стабильности лекарственного препарата, содержащий по меньшей мере один сухой порошок, полученный распылительной сушкой | |
| JP2004534813A5 (enExample) | ||
| EA201591415A1 (ru) | Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии | |
| JP2014062109A5 (enExample) | ||
| HK1215167A1 (zh) | 可吸入药用组合物和含有该药用组合物的吸入器装置 |